Topical treatment of actinic keratosis with imiquimod 5% cream

Garcez, T. N. A; Gerardi, D. G; Ferreira, K. C; Cardoso, C. S; Mõschbacher, P. D; Contesini, E. A.
Arq. bras. med. vet. zootec ; 64(6): 1524-1528, Dec. 2012. ilus
Artículo en Inglés | LILACS | ID: lil-660220

Documentos relacionados

  1. Topical treatment of actinic keratosis with imiquimod 5% cream
  2. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors.
  3. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody.
  4. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects.
  5. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways.
  6. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.
  7. [Bispecific Antibodies: Formats and Areas of Application].
  8. Anti-Hu antibodies activate enteric and sensory neurons.
  9. Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients.
  10. Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing.